Congress is out of session until Monday, November 9 for the midterm campaign. No new roll-call votes until then; the last were the House on Sep 16 and the Senate on Sep 30.

H.R. 6400 · 118th Congress · Health

To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.

Died in committee33 words Introduced Nov 14, 2023 · Latest action Dec 17, 2024

FollowRead the text
How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedNov 14, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 33 words

H.R. 6400 · Introduced in House · Nov 14, 2023

SECTION 1. EXTENDING ELIGIBILITY FOR CERTAIN PAYMENT INCREASES FOR BIOSIMILAR BIOLOGICAL PRODUCTS UNDER THE MEDICARE PROGRAM.

Section 1847A(b)(8)(B)(ii)(II) of the Social Security Act (42 U.S.C. 1395w–3a(b)(8)(B)(ii)(II)) is amended by striking 2027 and inserting 2032 .

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

1 organization · 5 filings · Q4 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. America's Health Insurance Plans Inc (ahip) 5 of 5 quarters
    “Draft, Medicare Compare Website (no bill number) - Rep. Guthrie, Brett - improvements to CMS Medicare compare website H.R. 3875 - Expanded Telehealth Access Act - Rep. Sherrill, Mikie - Medicare payment for telehealth services H.R. 4411 - Medicare Advantage Integrity Act - Resident Commissioner Gonzalez-Colon…”

    Q4 2024 filing · $11.8M lobbying spend in 2024, all issues

Organizations that named H.R. 6400 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

4 actions · newest first
  1. Dec 17, 2024Referred to the Subcommittee on Health.
  2. Nov 17, 2023Referred to the Subcommittee on Health.
  3. Nov 14, 2023Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Nov 14, 2023Introduced in House